The combination of ICB with key SASP factor-targeted therapies, such as NOTCH and TGF-a inhibitors, holds the potential to block or reverse SASP-induced immunosuppression, thereby enhancing anti-tumor response (42). This evidence concerns the gene TGFA and neoplasm.